Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

26.39 +1.53 (+6.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
99 100 Next >
Moderna’s Unexpected $217 Million Profit Marks A Surprising Q4 Achievement
Moderna Inc. showcased a resilient fourth-quarter performance for the fiscal year 2023, navigating through the challenges posed by the transition to an endemic market environment. 
Via Talk Markets
Nasdaq, S&P 500 Futures Jump As Nvidia Surge Raises 'FOMO' Rally Hopes: Analyst Tells Why Jobs Data Holds Key For Momentum
Market participants remain attentive to several factors shaping the day's trading landscape, including scheduled Fed speeches, weekly jobless claims data, and private-sector activity readings. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Why Range-Bound Moderna Could Get A Boost On Its Fourth-Quarter Report
The company unexpectedly came in with fourth-quarter earnings that beat projections. 
Via Investor's Business Daily
Moderna Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Updates
Via ACCESSWIRE
Peering Into Moderna's Recent Short Interest
Via Benzinga
Moderna's Options: A Look at What the Big Money is Thinking
Via Benzinga
Here's How Much You Would Have Made Owning Moderna Stock In The Last 5 Years
Via Benzinga
Earnings Scheduled For February 22, 2024
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million. 
Via Benzinga
Spotlight on Moderna: Analyzing the Surge in Options Activity
Via Benzinga
Moderna Likely To Report Q4 Loss; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Moderna, Inc. (NASDAQ: MRNA) is expected to release earnings results for its fourth quarter, before the opening bell on Feb. 22, 2024. 
Via Benzinga
Moderna Stock Q4 Earnings Preview: RSV mRNA Vaccine Scrutiny, Diminishing Spikevax Revenue, FDA Approval In Focus
Moderna reports Q4 earnings on Feb. 22. Analysts expect $2.53B in revenue. Stock has faced challenges but potential for recovery with COVID-19 vaccine and FDA approval in 2024. 
Via Benzinga
Exposures COVID-19 Product Safety
Looming Layoffs? 3 Companies That May Be the Next to Drop the Axe.
Layoffs were a big theme in 2023. Unless the economy drastically picks up in 2024, they could happen this year in large numbers. 
Via InvestorPlace
Topics Economy Workforce
Exposures Economy Layoff
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
To Sell or Not to Sell: How to Handle the Inevitable Nvidia Downturn
The NVDA stock outlook is complex, because there's a correction coming, and you don't want to be in it when it does. 
Via InvestorPlace
ChatGPT Stock Predictions: 3 Companies the AI Bot Thinks Have 10X Potential
Navigate the stock market with confidence using AI stock predictions. Harness the latest in AI technology for strategic investment planning. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
2 Stocks Down 36% or More to Buy and Hold for 10 Years
These companies have seen better days. 
Via The Motley Fool
3 Gene Editing Stocks With Unprecedented Surge Potential
While CRISPR will certainly be exciting to watch, here are some other gene-editing stocks with unprecedented surge potential. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
3 Doomed Biotech Stocks to Dump Before They Dive: February 2024
Spot the looming risks in the biotech sector and avoid these three doomed biotech stocks likely to burn shareholder value significantly. 
Via InvestorPlace
Why Is Moderna Stock Trading Lower Today?
Moderna long term data indicates a faster decline in efficacy for its RSV vaccine than the RSV vaccines from GSK and Pfizer. 
Via Benzinga
7 Stocks to Sell as Fast as You Possibly Can
Are you willing to sacrifice your returns just to hold on to these stocks? Each of them is a stock to sell now to save your portfolio. 
Via InvestorPlace
If You Invested $10,000 in Moderna in 2019, This Is How Much You Would Have Today
Moderna generated billions of dollars in earnings from its coronavirus vaccine. 
Via The Motley Fool
Exposures COVID-19
2024 Promises To Bring Pharmaceutical Breakthroughs On The Oncology Front
On Thursday, Merck & Co Inc (NYSE: MRK) topped estimates with its fourth quarter revenue and adjusted earnings fueled by its blockbuster cancer drug Keytruda, along with HPV prevention vaccine... 
Via Benzinga
Moderna Chief Executive Officer Stéphane Bancel Elected to National Academy of Engineering
Via ACCESSWIRE
3 Doomed Nasdaq Stocks to Dump Before They Dive: February 2024
Investors would be smart to steer clear of these companies, each of which is facing problems that seem insurmountable. 
Via InvestorPlace
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations
The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Pfizer Surprises With Profit But Revolutionizing Cancer Treatment Is Its Best Chance Of Getting Back In The Saddle
On Tuesday, Pfizer Inc (NYSE: PFE) reported mixed results for its fourth quarter. Last year, Pfizer has responded to concerns related to its COVID-19 products being the rearview mirror with a... 
Via Benzinga
Exposures COVID-19
Moderna to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
Via ACCESSWIRE
Moderna Named to Fortune's List of World's Most Admired Companies
Via ACCESSWIRE
Medicare's Historic Negotiations To Lower Drug Prices, Analysts Anticipate Upto Potential Price Cuts Of 60%
Explore the impact of the U.S. government's proposal on pharmaceuticals! Learn about Medicare's negotiation power, potential price cuts, and industry reactions. 
Via Benzinga
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS